Drugs Affecting Blood and Blood Formation Practice Questions

Q: Which of the following is a direct-acting thrombin inhibitor?

Hirudin. ### Explanation **Direct Thrombin Inhibitors (DTIs)** are anticoagulants that bind directly to thrombin (Factor IIa) and inhibit its activity without requiring a cofactor like Antithrombin III. **Why Hirudin is Correct:** Hirudin is a naturally occurring polypeptide originally found in the salivary glands of medicinal leeches (*Hirudo medicinalis*). It is a potent, irreversible, and **direct-acting thrombin inhibitor**. Unlike indirect inhibitors, it can neutralize both free-circulating thrombin and fibrin-bound thrombin within a clot. Synthetic analogs include Lepirudin, Desirudin, and Bivalirudin (parenteral), as well as Dabigatran (oral). **Why Other Options are Incorrect:** * **Heparin:** This is an **indirect thrombin inhibitor**. It requires the presence of a plasma cofactor, **Antithrombin III (AT-III)**, to exert its effect. Heparin binds to AT-III, causing a conformational change that accelerates the inactivation of Factor Xa and Thrombin. * **Warfarin:** This is an **oral anticoagulant** that acts as a Vitamin K antagonist. It inhibits the enzyme **VKORC1**, thereby preventing the γ-carboxylation of Vitamin K-dependent clotting factors (II, VII, IX, and X). It has no direct effect on thrombin itself. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** DTIs (like Argatroban or Bivalirudin) are the drugs of choice for patients who develop **Heparin-Induced Thrombocytopenia (HIT)**. * **Monitoring:** The effect of parenteral DTIs is monitored using **aPTT**. * **Oral DTI:** **Dabigatran** is the only oral DTI; its specific reversal agent is **Idarucizumab**. * **Bivalirudin** is a synthetic analog of Hirudin used primarily during Percutaneous Coronary Intervention (PCI).

Q: Platelet aggregation is inhibited by all except:

Thromboxane A2. **Explanation:** The correct answer is **Thromboxane A2 (TXA2)** because it is a potent **platelet aggregator** and vasoconstrictor, rather than an inhibitor. In the physiological process of hemostasis, activated platelets release TXA2 to recruit more platelets to the site of injury, facilitating the formation of a platelet plug. **Analysis of Options:** * **A. Aspirin:** It is an irreversible inhibitor of the enzyme **Cyclooxygenase-1 (COX-1)**. By inhibiting COX-1, it prevents the synthesis of Thromboxane A2, thereby inhibiting platelet aggregation for the lifetime of the platelet (7–10 days). * **B. Clopidogrel:** This is a P2Y12 receptor antagonist. It works by blocking the **ADP (Adenosine Diphosphate) receptor** on the platelet surface, which is a crucial pathway for platelet activation and subsequent aggregation. * **D. Eptifibatide:** This drug belongs to the class of **GP IIb/IIIa inhibitors**. Since the binding of fibrinogen to the GP IIb/IIIa receptor is the "final common pathway" for platelet aggregation, blocking this receptor provides potent antiplatelet effects. **NEET-PG High-Yield Pearls:** * **Aspirin** is used in low doses (75–150 mg) for cardioprotection because it selectively inhibits TXA2 in platelets without significantly affecting PGI2 (prostacyclin) in endothelial cells. * **Abciximab** is a monoclonal antibody against GP IIb/IIIa, while **Eptifibatide** and **Tirofiban** are synthetic peptides/non-peptides. * **Dipyridamole** and **Cilostazol** inhibit platelet aggregation by increasing intra-platelet cAMP levels via Phosphodiesterase (PDE) inhibition. * **Prostacyclin (PGI2)** is a natural inhibitor of aggregation, acting as a physiological antagonist to TXA2.

Q: An elderly patient on warfarin therapy for deep vein thrombosis presents with a nosebleed. Her INR is found to be 7.0. In addition to discontinuing warfarin, what is the most appropriate next step to manage the hemorrhagic risk?

Vitamin K1. **Explanation:** The patient is experiencing **Warfarin toxicity**, characterized by an elevated International Normalized Ratio (INR) and active bleeding. Warfarin acts as a Vitamin K antagonist by inhibiting the enzyme **Vitamin K Epoxide Reductase (VKOR)**, which prevents the gamma-carboxylation (activation) of clotting factors II, VII, IX, and X. **Why Vitamin K1 is correct:** Vitamin K1 (Phytonadione) is the specific antidote for warfarin. It bypasses the inhibited VKOR enzyme to provide a source for the synthesis of functional clotting factors. According to clinical guidelines, for an INR > 10 or INR > 4.5 with bleeding, Vitamin K is indicated. In cases of life-threatening hemorrhage, Vitamin K is supplemented with Prothrombin Complex Concentrate (PCC) or Fresh Frozen Plasma (FFP) for immediate effect. **Why other options are incorrect:** * **Desmopressin (dDAVP):** Used to increase levels of Factor VIII and von Willebrand factor; it is the treatment for von Willebrand disease and mild Hemophilia A, not warfarin reversal. * **Factor VIII:** Specifically used for Hemophilia A. Warfarin affects multiple factors (II, VII, IX, X), so replacing only Factor VIII is ineffective. * **Protamine sulfate:** This is the specific antidote for **Heparin** overdose, acting via chemical neutralization. **NEET-PG High-Yield Pearls:** * **Monitoring:** Warfarin is monitored by **PT/INR** (Extrinsic pathway), while Heparin is monitored by **aPTT** (Intrinsic pathway). * **Half-life:** Factor VII has the shortest half-life (6 hours), making it the first to decline and the first to be reflected in an increased INR. * **Teratogenicity:** Warfarin is contraindicated in pregnancy (causes Fetal Warfarin Syndrome/Chondrodysplasia punctata); Heparin is the preferred anticoagulant for pregnant women.

Q: What is the anticoagulant of choice during pregnancy?

Heparin. The anticoagulant of choice during pregnancy is **Heparin** (specifically Low Molecular Weight Heparin or Unfractionated Heparin). **1. Why Heparin is Correct:** The primary medical concept here is the **Placental Barrier**. Heparin is a large, polar, acidic polysaccharide molecule with a high molecular weight [1]. Due to these characteristics, it **does not cross the placenta** and therefore does not enter the fetal circulation [2]. Consequently, it carries no risk of causing fetal malformations or systemic anticoagulation in the fetus. **2. Why Incorrect Options are Wrong:** * **Warfarin (Option B):** Warfarin is a small, lipid-soluble molecule that easily crosses the placenta [2]. It is highly **teratogenic**, especially during the first trimester (6th–9th week), leading to **Fetal Warfarin Syndrome** (characterized by nasal hypoplasia, stippled epiphyses, and CNS defects). It can also cause fetal intracranial hemorrhage during labor. * **Dicumarol (Option C) & Phenindione (Option D):** These are older oral anticoagulants (coumarin derivatives) similar to Warfarin. Like Warfarin, they cross the placenta and pose significant risks of teratogenicity and fetal hemorrhage. **3. NEET-PG High-Yield Pearls:** * **LMWH (e.g., Enoxaparin)** is generally preferred over Unfractionated Heparin (UFH) in pregnancy due to a better safety profile, longer half-life, and lower risk of Heparin-Induced Thrombocytopenia (HIT) and osteoporosis [1]. * **Warfarin exception:** In women with **mechanical heart valves**, the risk of valve thrombosis is so high that Warfarin may be used during the second trimester, but it must be switched back to Heparin near term. * **Breastfeeding:** Both Heparin and Warfarin are considered **safe during breastfeeding** as they do not pass into breast milk in significant amounts.

Q: Which clotting parameter is most likely to be increased in Vitamin K deficiency?

Prothrombin Time (PT). **Explanation:** Vitamin K is an essential cofactor for the enzyme **gamma-glutamyl carboxylase**, which is responsible for the post-translational modification (gamma-carboxylation) of clotting **factors II, VII, IX, and X**, as well as proteins C and S. **Why PT is the correct answer:** Among these factors, **Factor VII** has the shortest half-life (approximately 4–6 hours). Because Factor VII is a key component of the **extrinsic pathway**, its rapid decline in Vitamin K deficiency leads to an early and significant prolongation of the **Prothrombin Time (PT)**. While the intrinsic pathway (measured by PTT) is eventually affected due to declines in factors IX, X, and II, the PT is the most sensitive and earliest indicator of Vitamin K deficiency. **Analysis of Incorrect Options:** * **A. Partial Thromboplastin Time (PTT):** This measures the intrinsic and common pathways. While PTT can increase in severe Vitamin K deficiency (due to low factors IX, X, and II), it is less sensitive than PT because the involved factors have longer half-lives than Factor VII. * **C. Platelet count:** Vitamin K deficiency affects soluble clotting factors, not the production or consumption of platelets. * **D. Fibrinogen time (Thrombin Time):** This measures the conversion of fibrinogen to fibrin. It is affected by heparin or hypofibrinogenemia, not by Vitamin K status. **High-Yield NEET-PG Pearls:** * **Warfarin** mechanism: Inhibits Vitamin K Epoxide Reductase (VKOR), mimicking Vitamin K deficiency. * **Newborns** are routinely given Vitamin K prophylaxis because they have sterile guts (no Vitamin K-producing bacteria) and poor placental transfer. * **PIVKA** (Proteins Induced by Vitamin K Absence) are non-functional precursors that circulate in deficiency states.

Q: Vascular dermal necrosis is seen with which of the following drugs?

Warfarin. **Explanation:** **Warfarin-induced Skin Necrosis (WISN)** is a rare but severe complication occurring typically within 3–10 days of starting therapy. **Why Warfarin is the Correct Answer:** Warfarin acts by inhibiting Vitamin K Epoxide Reductase (VKOR), leading to a depletion of Vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins (Protein C and Protein S). * **The Mechanism:** Protein C has a significantly shorter half-life (~6 hours) compared to procoagulant factors like Factor X and II. * **The Result:** During the initial phase of treatment, Protein C levels drop rapidly while procoagulant factors remain active. This creates a transient **hypercoagulable state**, leading to microvascular thrombosis in the dermal capillaries, resulting in vascular dermal necrosis. This is why "bridging" with Heparin is clinically essential. **Why Other Options are Incorrect:** * **B, C, and D (Hirudin, Dabigatran, Rivaroxaban):** These are Direct Thrombin Inhibitors (Hirudin, Dabigatran) or Direct Factor Xa Inhibitors (Rivaroxaban). Unlike Warfarin, they do not affect the synthesis of Protein C or S and do not create an initial prothrombotic window. Therefore, they are not associated with skin necrosis. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factor:** Patients with an underlying **Protein C deficiency** are at the highest risk for Warfarin-induced skin necrosis. * **Common Sites:** Areas with high subcutaneous fat (breasts, thighs, buttocks). * **Management:** Immediate discontinuation of Warfarin, administration of Vitamin K, and starting therapeutic Heparin. * **Purple Toe Syndrome:** Another Warfarin-related skin complication caused by cholesterol microembolization (distinct from necrosis).

Q: What is a primary indication for the use of anticoagulants?

Venous thrombosis. **Explanation:** **1. Why Venous Thrombosis is Correct:** Anticoagulants (such as Heparin and Warfarin) primarily work by interfering with the coagulation cascade to prevent the formation or extension of **fibrin-rich "red thrombi."** These thrombi typically form in areas of low blood flow, such as the deep veins of the legs (**Deep Vein Thrombosis**) or the pulmonary vasculature (**Pulmonary Embolism**). Therefore, anticoagulants are the mainstay for the prevention and treatment of venous thromboembolism (VTE). **2. Why the Other Options are Incorrect:** * **Arterial Thrombosis (Option B):** While anticoagulants are used in specific arterial conditions (like AFib or ACS), arterial thrombi are primarily **platelet-rich "white thrombi"** formed under high-shear stress. **Antiplatelet drugs** (e.g., Aspirin, Clopidogrel) are generally the first-line treatment for arterial thrombosis. * **Vitamin K Toxicity (Option C):** This is incorrect because Vitamin K is actually the **antidote** used to reverse the effects of Warfarin (an anticoagulant). Anticoagulants would worsen bleeding risks in this context. * **Heart Failure (Option D):** Heart failure is a structural/functional pump failure. While patients with severe heart failure may eventually require anticoagulation if they develop atrial fibrillation or mural thrombi, it is not a primary indication for the drug class itself. **3. NEET-PG High-Yield Pearls:** * **Mechanism:** Heparin acts via **Antithrombin III** (inhibits Factors IIa and Xa); Warfarin inhibits **VKORC1** (inhibits Factors II, VII, IX, X, Protein C, and S). * **Monitoring:** Monitor Heparin with **aPTT** and Warfarin with **PT/INR**. * **Drug of Choice:** LMWH (Enoxaparin) is the preferred anticoagulant in **pregnancy** as it does not cross the placenta. * **Antidotes:** Protamine sulfate for Heparin; Vitamin K or FFP/PCC for Warfarin.

Q: Which of the following is an example of low molecular weight heparin?

Enoxaparin. **Explanation:** **Correct Option: C. Enoxaparin** Low Molecular Weight Heparins (LMWHs) are derived from unfractionated heparin (UFH) through chemical or enzymatic depolymerization. **Enoxaparin** is the most commonly used LMWH. These drugs act primarily by inhibiting **Factor Xa** via antithrombin III, with minimal effect on Thrombin (Factor IIa). Other examples include Dalteparin, Nadroparin, and Tinzaparin (remember the suffix **"-parin"**). **Analysis of Incorrect Options:** * **A. Alteplase:** This is a **Thrombolytic** (Fibrinolytic) agent. It is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin, which then degrades fibrin clots. * **B & D. Lepirudin and Hirudin:** These are **Direct Thrombin Inhibitors (DTIs)**. Hirudin is a natural anticoagulant derived from leech saliva, and Lepirudin is its recombinant derivative. They bind directly to thrombin without requiring antithrombin III as a cofactor. **High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** Unlike UFH, LMWHs do not require routine aPTT monitoring due to their predictable bioavailability and pharmacokinetics. * **Renal Clearance:** LMWHs are primarily excreted by the kidneys; therefore, they are **contraindicated in renal failure** (CrCl <30 ml/min). UFH is the drug of choice in such patients. * **Antidote:** Protamine sulfate can completely neutralize UFH, but it only **partially neutralizes** LMWH. * **HIT:** LMWHs have a lower risk of causing Heparin-Induced Thrombocytopenia (HIT) compared to UFH.

Q: All of the following statements about unfractionated heparin are true except?

It is a powerful anticoagulant only in vivo. **Explanation:** The correct answer is **A**, as the statement "It is a powerful anticoagulant only in vivo" is false. **1. Why Option A is the correct answer (False statement):** Unfractionated Heparin (UFH) acts by binding to **Antithrombin III (AT-III)**, which is a naturally occurring plasma protein. Because AT-III is present both in circulating blood and in collected blood samples, heparin is effective **both in vivo (inside the body) and in vitro (outside the body)**. This is why heparinized tubes are used in laboratories to prevent blood from clotting after collection. In contrast, oral anticoagulants like Warfarin work only *in vivo* because they interfere with the hepatic synthesis of clotting factors. **2. Analysis of Incorrect Options (True statements):** * **Option B:** Protamine sulfate is a strongly basic protein that ionically binds to acidic heparin to form a stable, inactive complex. It is the specific chemical antagonist used to reverse heparin overdose. * **Option C:** Heparin should **never be given intramuscularly (IM)** because it can cause large, painful hematomas due to the high vascularity of muscle tissue and the drug's potent anticoagulant effect. * **Option D:** The heparin-AT-III complex inactivates several clotting factors, most significantly **Thrombin (IIa) and Factor Xa** (in a 1:1 ratio). **Clinical Pearls for NEET-PG:** * **Monitoring:** UFH is monitored using **aPTT** (Target: 1.5–2.5 times the control). * **Side Effects:** The most common side effect is bleeding; the most unique is **Heparin-Induced Thrombocytopenia (HIT)**. * **LMWH vs. UFH:** Low Molecular Weight Heparins (e.g., Enoxaparin) mainly inhibit Factor Xa and do not require routine aPTT monitoring. * **Pregnancy:** Heparin is the **anticoagulant of choice during pregnancy** as it does not cross the placenta.

Question 1

Which of the following is a direct-acting thrombin inhibitor?

Accepted Answer

Hirudin

Answer

Heparin

Answer

Warfarin

Answer

All of the above

Question 2

Platelet aggregation is inhibited by all except:

Accepted Answer

Thromboxane A2

Answer

Aspirin

Answer

Clopidogrel

Answer

Eptifibatide

Question 3

An elderly patient on warfarin therapy for deep vein thrombosis presents with a nosebleed. Her INR is found to be 7.0. In addition to discontinuing warfarin, what is the most appropriate next step to manage the hemorrhagic risk?

Accepted Answer

Vitamin K1

Answer

Desmopressin

Answer

Factor VIII

Answer

Protamine sulfate

Question 4

The anticoagulant action of warfarin is potentiated by all of the following EXCEPT:

Accepted Answer

Both 2 and 3

Answer

Phenylbutazone

Answer

Vitamin K

Answer

Rifampicin

Question 5

What is the anticoagulant of choice during pregnancy?

Accepted Answer

Heparin

Answer

Warfarin

Answer

Dicumarol

Answer

Phenindione

Question 6

Which clotting parameter is most likely to be increased in Vitamin K deficiency?

Accepted Answer

Prothrombin Time (PT)

Answer

Partial Thromboplastin Time (PTT)

Answer

Platelet count

Answer

Fibrinogen time

Question 7

Vascular dermal necrosis is seen with which of the following drugs?

Accepted Answer

Warfarin

Answer

Hirudin

Answer

Dabigatran

Answer

Rivaroxaban

Question 8

What is a primary indication for the use of anticoagulants?

Accepted Answer

Venous thrombosis

Answer

Aerial thrombosis

Answer

Vitamin K toxicity

Answer

Heart failure

Question 9

Which of the following is an example of low molecular weight heparin?

Accepted Answer

Enoxaparin

Answer

Alteplase

Answer

Lepirudin

Answer

Hirudin

Question 10

All of the following statements about unfractionated heparin are true except?

Accepted Answer

It is a powerful anticoagulant only in vivo

Answer

Protamine sulfate is the antidote

Answer

It should not be given by intramuscular route

Answer

It acts by inhibiting factor IIa and Xa

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?